Twenty-eight dogs with histologically, cytologically confirmed or presumed heart based tumors were evaluated. Twenty-seven of the dogs were treated with toceranib alone. An overall response rate of 10% was found and the  median survival time was 823 days (range, 68-1190 days). The overall response rate for the dogs presenting with metastasis was 28.5%, with a median survival time of 532 days (range, 77-679 days). This was not significantly different than the median survival time of 796 days for dogs who did not present with metastasis. Of the dogs displaying clinical signs at the time of diagnosis, 90% had improvement and 81% had complete resolution of signs after starting toceranib. Drug toxicity was seen in 54% of dogs with gastrointestinal distress as the most common adverse effect.  Results of this study suggests that toceranib phosphate is well-tolerated and effective treatment for inoperable canine heart based tumors including dogs with advanced or metastatic disease.

Read more by clicking on the link below:

Retrospective evaluation of canine heart base tumors treated with toceranib phosphate (Palladia®): 2011‐2018